SCHEMBL3530571

SCHEMBL3530571

Cc1ccc2ccc(C=O)nc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.55
ALDH1A1 P00352 6/20 0.54
KDM4E B2RXH2 2/20 0.51
GAA P10253 1/20 0.51
PFKFB3 Q16875 1/20 0.51
CCR1 P32246 1/20 0.48
ESR1 P03372 1/20 0.42
CYP2A6 P11509 3/20 0.41
NQO2 P16083 1/20 0.41
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
F2R P25116 1/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
NFKB1 P19838 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TERT O14746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10740204 0.86 CYP1A2 (0.57) CYP1A2ALDH1A1KDM4EGAAPFKFB3
SCHEMBL10974039 0.80 CYP1A2 (0.49) CYP1A2ALDH1A1KDM4EGAAPFKFB3
SCHEMBL28621619 0.78 CCR1 (0.50) ALDH1A1KDM4ECCR1CYP2A6KMT2A
SCHEMBL28280669 0.77 KDM4E (0.51) CYP1A2ALDH1A1KDM4EGAACCR1
SCHEMBL2169969 0.76 CCR1 (0.48) CYP1A2ALDH1A1KDM4ECCR1CYP2A6
SCHEMBL18572379 0.76 CCR1 (0.48) CYP1A2ALDH1A1KDM4EGAAPFKFB3
SCHEMBL29954808 0.76 CCR1 (0.48) CYP1A2ALDH1A1KDM4EGAAPFKFB3
SCHEMBL3748357 0.76 CCR1 (0.48) ALDH1A1KDM4ECCR1KMT2ANPSR1
SCHEMBL2016701 0.76 BACE1 (0.52) CYP1A2ALDH1A1KDM4ECCR1CYP2A6
SCHEMBL2672759 0.76 TERT (0.60) ALDH1A1KDM4EGAACCR1CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10010542-B2 PFKFB3 inhibit and methods of use as an anti-cancer therapeutic GB ACT, INC. (US) 2018-07-03 US disclosed
US-20170258783-A1 PFKFB3 INHIBIT AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC GB005, INC. 2017-09-14 US disclosed
US-9649305-B2 PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic ADVANCED CANCER THERAPEUTICS, LLC (US) 2017-05-16 US disclosed
US-20150064175-A1 PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC GB005, INC. 2015-03-05 US disclosed
US-8071620-B2 Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2011-12-06 US disclosed
US-20100093743-A1 CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2010-04-15 US disclosed
US-7652036-B2 Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2010-01-26 US disclosed
US-20060079528-A1 (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer TOPOTARGET UK LIMITED (GB) 2006-04-13 US disclosed
EP-1599449-A2 CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS TopoTarget UK Limited (GB) 2005-11-30 EP disclosed
WO-2004076386-A2 CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2004-09-10 WO disclosed
US-4017313-A Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258783-A1 PFKFB3 INHIBIT AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC PFKFB3, PFKFB1, PFKFB2 CYP1A2 2493/4885ALDH1A1 1250/4885KDM4E 708/4885
US-20060079528-A1 (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer HDAC1, HDAC11, HDAC5 CYP1A2 2188/4885ALDH1A1 1467/4885KDM4E 35/4885
US-10010542-B2 PFKFB3 inhibit and methods of use as an anti-cancer therapeutic PFKFB3, PFKFB1, PFKFB2 CYP1A2 2493/4885ALDH1A1 1250/4885KDM4E 708/4885
US-20150064175-A1 PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC PFKFB3, PFKFB1, PFKFB2 CYP1A2 2362/4885ALDH1A1 1310/4885KDM4E 710/4885
US-20100093743-A1 CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS HDAC1, HDAC7, HDAC5 CYP1A2 1355/4885ALDH1A1 1740/4885KDM4E 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.